This website uses cookies primarily for visitor analytics. Certain pages will ask you to fill in contact details to receive additional information. On these pages you have the option of having the site log your details for future visits. Indicating you want the site to remember your details will place a cookie on your device. To view our full cookie policy, please click here. You can also view it at any time by going to our Contact Us page.

Motion solution requirements for biologic delivery devices

Author : Jigar Fulia and Kanti Vala, Portescap

31 August 2022

From cancer to rheumatoid arthritis, biopharmaceuticals have revolutionised treatments, in some cases providing hope for patients who previously had no further options. Integral to their success are the delivery devices, which are driven by accurate, reliable motion systems.

Whether intended for disposable use or long-term administration, a tailored motion system will help the OEM best meet patient needs. Here, Portescap’s Jigar Fulia and Kanti Vala consider the selection criteria for biologics system motion solutions.

Commonly known as biologics, these drugs are manufactured in or from a biological source, unlike typical medication which is developed through chemical synthesis. The advantage is that biologics change the way the human immune system reacts, down-regulating the inflammatory response or supporting tumour-specific defence.

Biologics are delivered by injection and as they have a much higher molecular weight than traditional, small-molecule chemical drugs, they are far more viscous. This makes accuracy in injecting the drugs increasingly critical. The drugs are typically administered at regular intervals over a set time frame. Reliance for this task is placed on the delivery mechanism, which is driven by a miniaturised motion solution. 

Read the full article in DPA's September issue

Contact Details and Archive...

Print this page | E-mail this page